Regulators have granted approval for home-based self-administration of Intranasal Foralumab, a treatment developed by Tiziana Life Sciences Ltd (NASDAQ:TLSA).
Sign-off by the US Food and Drug Administration (FDA) for this approach marks a major step forward in making treatment more accessible and convenient for those grappling with the debilitating condition.
The FDA's decision comes after the development and refinement of delivery device training materials, produced in collaboration with Tiziana Life Sciences. Patients will receive training on how to use the nasal system, in line with these guidelines.
“Traditionally, MS patients have had to visit healthcare facilities for treatment, which could be inconvenient and burdensome," said Tiziana chairman and founder Gabriele Cerrone.
"The FDA's approval for home dosing of Foralumab will transform the way patients manage their condition, offering them greater control over their treatment schedules and the convenience of receiving care in their familiar environment.
"We are elated with the FDA's allowance for home dosing of Intranasal Foralumab. This step significantly aligns with our mission to make innovative therapies more accessible to patients and ultimately improve their quality of life.
"We believe that this treatment approach will revolutionize the way multiple sclerosis patients manage their condition."
Intranasal Foralumab has shown promise in managing MS, and the FDA's approval for home use further enhances its potential as a game-changing therapy.